Entries by Peggy Bickerton

Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI® (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes

/in ,

Study achieved median overall survival of 31.7 months Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response INQOVI is the only oral hypomethylating agent with equivalent exposure to its intravenous (IV) form Pleasanton, CA, September 23, 2021. Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka […]

NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology

/in ,

For Immediate Release: April 14, 2021Media Contact:Rachel Darwin267-622-6624darwin@nccn.org NCCN Oncology Research Program to oversee projects exploring oral medication combination targeting tumor suppression genes. PLYMOUTH MEETING, PA [April 14, 2021] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and […]